These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34666046)

  • 1. Fatty Acids Can Induce the Formation of Proteinaceous Particles in Monoclonal Antibody Formulations.
    Zhang J; He J; Smith KJ
    J Pharm Sci; 2022 Mar; 111(3):655-662. PubMed ID: 34666046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Comprehensive Assessment of All-Oleate Polysorbate 80: Free Fatty Acid Particle Formation, Interfacial Protection and Oxidative Degradation.
    Doshi N; Giddings J; Luis L; Wu A; Ritchie K; Liu W; Chan W; Taing R; Chu J; Sreedhara A; Kannan A; Kei P; Shieh I; Graf T; Hu M
    Pharm Res; 2021 Mar; 38(3):531-548. PubMed ID: 33713012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving Prediction of Free Fatty Acid Particle Formation in Biopharmaceutical Drug Products: Incorporating Ester Distribution during Polysorbate 20 Degradation.
    Doshi N; Martin J; Tomlinson A
    Mol Pharm; 2020 Nov; 17(11):4354-4363. PubMed ID: 32941040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Free fatty acid particles in protein formulations, part 2: contribution of polysorbate raw material.
    Siska CC; Pierini CJ; Lau HR; Latypov RF; Fesinmeyer RM; Litowski JR
    J Pharm Sci; 2015 Feb; 104(2):447-56. PubMed ID: 25196966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polysorbate Degradation and Particle Formation in a High Concentration mAb: Formulation Strategies to Minimize Effect of Enzymatic Polysorbate Degradation.
    Roy I; Patel A; Kumar V; Nanda T; Assenberg R; Wuchner K; Amin K
    J Pharm Sci; 2021 Sep; 110(9):3313-3323. PubMed ID: 34077768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzymatic degradation pattern of polysorbate 20 impacts interfacial properties of monoclonal antibody formulations.
    Gregoritza K; Theodorou C; Heitz M; Graf T; Germershaus O; Gregoritza M
    Eur J Pharm Biopharm; 2024 Jan; 194():74-84. PubMed ID: 38042510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding Particle Formation: Solubility of Free Fatty Acids as Polysorbate 20 Degradation Byproducts in Therapeutic Monoclonal Antibody Formulations.
    Doshi N; Demeule B; Yadav S
    Mol Pharm; 2015 Nov; 12(11):3792-804. PubMed ID: 26419285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An in-depth examination of fatty acid solubility limits in biotherapeutic protein formulations containing polysorbate 20 and polysorbate 80.
    Glücklich N; Dwivedi M; Carle S; Buske J; Mäder K; Garidel P
    Int J Pharm; 2020 Dec; 591():119934. PubMed ID: 33059015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stress-mediated polysorbate 20 degradation and its potential impact on therapeutic proteins.
    Aryal B; Lehtimaki M; Rao VA
    Pharm Res; 2024 Jun; 41(6):1217-1232. PubMed ID: 38740663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Existence of a superior polysorbate fraction in respect to protein stabilization and particle formation?
    Diederichs T; Mittag JJ; Humphrey J; Voss S; Carle S; Buske J; Garidel P
    Int J Pharm; 2023 Mar; 635():122660. PubMed ID: 36740078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polysorbate 20 Degradation in Biopharmaceutical Formulations: Quantification of Free Fatty Acids, Characterization of Particulates, and Insights into the Degradation Mechanism.
    Tomlinson A; Demeule B; Lin B; Yadav S
    Mol Pharm; 2015 Nov; 12(11):3805-15. PubMed ID: 26419339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of Polysorbate Ester Fractions and Implications in Protein Drug Product Stability.
    Tomlinson A; Zarraga IE; Demeule B
    Mol Pharm; 2020 Jul; 17(7):2345-2353. PubMed ID: 32442382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Subvisible Particles in Biopharmaceutical Formulations Using Raman Spectroscopy Provides Insight into Polysorbate 20 Degradation Pathway.
    Saggu M; Liu J; Patel A
    Pharm Res; 2015 Sep; 32(9):2877-88. PubMed ID: 25773722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Protein Particle Formation in IgG1 mAbs Formulated with PS20 Vs. PS80 When Subjected to Interfacial Dilatational Stress.
    Vaclaw C; Merritt K; Griffin VP; Whitaker N; Gokhale M; Volkin DB; Ogunyankin MO; Dhar P
    AAPS PharmSciTech; 2023 Apr; 24(5):104. PubMed ID: 37081185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Degradation of Polysorbate 20 by Sialate O-Acetylesterase in Monoclonal Antibody Formulations.
    Zhang S; Xiao H; Li N
    J Pharm Sci; 2021 Dec; 110(12):3866-3873. PubMed ID: 34487744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Polysorbate 80 Grade on the Interfacial Properties and Interfacial Stress Induced Subvisible Particle Formation in Monoclonal Antibodies.
    Vaclaw C; Merritt K; Pringle V; Whitaker N; Gokhale M; Carvalho T; Pan D; Liu Z; Bindra D; Khossravi M; Bolgar M; Volkin DB; Ogunyankin MO; Dhar P
    J Pharm Sci; 2021 Feb; 110(2):746-759. PubMed ID: 32987092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metal-Induced Fatty Acid Particle Formation Resulting from Hydrolytic Polysorbate Degradation.
    Gregoritza K; Cai SK; Siketanc M; Woehr A; Lebouc V; Kishore RSK; Nicoulin V; Bleher S; Allmendinger A
    J Pharm Sci; 2022 Mar; 111(3):743-751. PubMed ID: 34600939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Free fatty acid particles in protein formulations, part 1: microspectroscopic identification.
    Cao X; Fesinmeyer RM; Pierini CJ; Siska CC; Litowski JR; Brych S; Wen ZQ; Kleemann GR
    J Pharm Sci; 2015 Feb; 104(2):433-46. PubMed ID: 25175016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polysorbates versus Hydroxypropyl Beta-Cyclodextrin (HPβCD): Comparative Study on Excipient Stability and Stabilization Benefits on Monoclonal Antibodies.
    Zhang H; Hong S; Tan SSK; Peng T; Goh LYH; Lam KH; Chow KT; Gokhale R
    Molecules; 2022 Oct; 27(19):. PubMed ID: 36235038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Super Refined™ Polysorbate 20 With Respect to Polysorbate Degradation, Particle Formation and Protein Stability.
    Doshi N; Fish R; Padilla K; Yadav S
    J Pharm Sci; 2020 Oct; 109(10):2986-2995. PubMed ID: 32679214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.